Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 77

1.

The German Hodgkin Study Group risk model is useful for Hodgkin lymphoma patients receiving radiotherapy after autologous stem cell transplant.

Furlan C, Matrone F, Rupolo M, Ciancia R, Zanet E, Montante B, Palazzari E, Navarria F, Trovo M, Bulian P, Spina M, Coassin E, Mascarin M, De Paoli A, Franchin G, Michieli M.

Cancer Radiother. 2019 Jun 6. pii: S1278-3218(19)30085-X. doi: 10.1016/j.canrad.2019.02.002. [Epub ahead of print]

PMID:
31178272
2.

A high definition picture of key genes and pathways mutated in pediatric follicular lymphoma.

Lovisa F, Binatti A, Coppe A, Primerano S, Carraro E, Pillon M, Pizzi M, Guzzardo V, Buffardi S, Porta F, Farruggia P, De Santis R, Bulian P, Basso G, Lazzari E, d'Amore ESG, Bortoluzzi S, Mussolin L.

Haematologica. 2019 Feb 28. pii: haematol.2018.211631. doi: 10.3324/haematol.2018.211631. [Epub ahead of print]

3.

A B-cell receptor-related gene signature predicts response to ibrutinib treatmeant in mantle cell lymphoma cell lines.

D'Agaro T, Zucchetto A, Vit F, Bittolo T, Tissino E, Rossi FM, Degan M, Zaja F, Bulian P, Dal Bo M, Ferrero S, Ladetto M, Zamò A, Gattei V, Bomben R.

Haematologica. 2019 Feb 28. pii: haematol.2018.212811. doi: 10.3324/haematol.2018.212811. [Epub ahead of print]

4.

Survival and Prognostic Factors in Mixed Cryoglobulinemia: Data from 246 Cases.

Mazzaro C, Maso LD, Mauro E, Gattei V, Ghersetti M, Bulian P, Moratelli G, Grassi G, Zorat F, Pozzato G.

Diseases. 2018 May 3;6(2). pii: E35. doi: 10.3390/diseases6020035.

5.

Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia.

Tissino E, Benedetti D, Herman SEM, Ten Hacken E, Ahn IE, Chaffee KG, Rossi FM, Dal Bo M, Bulian P, Bomben R, Bayer E, Härzschel A, Gutjahr JC, Postorino M, Santinelli E, Ayed A, Zaja F, Chiarenza A, Pozzato G, Chigaev A, Sklar LA, Burger JA, Ferrajoli A, Shanafelt TD, Wiestner A, Del Poeta G, Hartmann TN, Gattei V, Zucchetto A.

J Exp Med. 2018 Feb 5;215(2):681-697. doi: 10.1084/jem.20171288. Epub 2018 Jan 4.

6.

Mutational status of IGHV is the most reliable prognostic marker in trisomy 12 chronic lymphocytic leukemia.

Bulian P, Bomben R, Bo MD, Zucchetto A, Rossi FM, Degan M, Pozzo F, Bittolo T, Bravin V, D'Agaro T, Cerri M, Chiarenza A, Chaffee KG, Condoluci A, D'Arena G, Spina M, Zaja F, Pozzato G, Di Raimondo F, Rossi D, Poeta GD, Gaidano G, Shanafelt TD, Gattei V.

Haematologica. 2017 Nov;102(11):e443-e446. doi: 10.3324/haematol.2017.170340. Epub 2017 Jul 27. No abstract available.

7.

NOTCH1 mutational status in chronic lymphocytic leukaemia: clinical relevance of subclonal mutations and mutation types.

D'Agaro T, Bittolo T, Bravin V, Dal Bo M, Pozzo F, Bulian P, Rossi FM, Zucchetto A, Degan M, D'Arena G, Chiarenza A, Zaja F, Pozzato G, Di Raimondo F, Rossi D, Gaidano G, Del Poeta G, Gattei V, Bomben R.

Br J Haematol. 2018 Aug;182(4):597-602. doi: 10.1111/bjh.14843. Epub 2017 Jul 12. No abstract available.

PMID:
28699643
8.

Mutations in the 3' untranslated region of NOTCH1 are associated with low CD20 expression levels chronic lymphocytic leukemia.

Bittolo T, Pozzo F, Bomben R, D'Agaro T, Bravin V, Bulian P, Rossi FM, Zucchetto A, Degan M, Macor P, D'Arena G, Chiarenza A, Zaja F, Pozzato G, Di Raimondo F, Rossi D, Gaidano G, Del Poeta G, Gattei V, Dal Bo M.

Haematologica. 2017 Aug;102(8):e305-e309. doi: 10.3324/haematol.2016.162594. Epub 2017 May 26. No abstract available.

9.

NOTCH1-mutated chronic lymphocytic leukemia cells are characterized by a MYC-related overexpression of nucleophosmin 1 and ribosome-associated components.

Pozzo F, Bittolo T, Vendramini E, Bomben R, Bulian P, Rossi FM, Zucchetto A, Tissino E, Degan M, D'Arena G, Di Raimondo F, Zaja F, Pozzato G, Rossi D, Gaidano G, Del Poeta G, Gattei V, Dal Bo M.

Leukemia. 2017 Nov;31(11):2407-2415. doi: 10.1038/leu.2017.90. Epub 2017 Mar 21.

PMID:
28321119
10.

Low-dose radiotherapy in diffuse large B-cell lymphoma.

Furlan C, Canzonieri V, Spina M, Michieli M, Ermacora A, Maestro R, Piccinin S, Bomben R, Dal Bo M, Trovo M, Gattei V, Tirelli U, Franchin G, Bulian P.

Hematol Oncol. 2017 Dec;35(4):472-479. doi: 10.1002/hon.2368. Epub 2016 Oct 25.

PMID:
27781290
11.

Functional and Clinical Significance of the Integrin Alpha Chain CD49d Expression in Chronic Lymphocytic Leukemia.

Dal Bo M, Tissino E, Benedetti D, Caldana C, Bomben R, Poeta GD, Gaidano G, Rossi FM, Bulian P, Zucchetto A, Gattei V.

Curr Cancer Drug Targets. 2016;16(8):659-668. Review.

PMID:
27514846
12.

CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia.

Dal Bo M, Bulian P, Bomben R, Zucchetto A, Rossi FM, Pozzo F, Tissino E, Benedetti D, Bittolo T, Nanni P, Cattarossi I, Zaina E, Chivilò H, Degan M, Zaja F, Pozzato G, Chiarenza A, Di Raimondo F, Del Principe MI, Del Poeta G, Rossi D, Gaidano G, Gattei V.

Leukemia. 2016 Oct;30(10):2011-2018. doi: 10.1038/leu.2016.88. Epub 2016 Apr 25.

PMID:
27109509
13.

Primary Non-Hodgkin's Lymphoma of the Vulva: A Case Report and Literature Review.

Clemente N, Alessandrini L, Rupolo M, Bulian P, Lucia E, Canzonieri V, Sopracordevole F.

Medicine (Baltimore). 2016 Mar;95(10):e3041. doi: 10.1097/MD.0000000000003041. Review.

14.

Hepatitis C virus and non-Hodgkin's lymphomas: Meta-analysis of epidemiology data and therapy options.

Pozzato G, Mazzaro C, Dal Maso L, Mauro E, Zorat F, Moratelli G, Bulian P, Serraino D, Gattei V.

World J Hepatol. 2016 Jan 18;8(2):107-16. doi: 10.4254/wjh.v8.i2.107. Review.

15.

Functional osteoclastogenesis: the baseline variability in blood donor precursors is not associated with age and gender.

Pivetta E, Wassermann B, Bulian P, Steffan A, Colombatti A, Polesel J, Spessotto P.

Oncotarget. 2015 Oct 13;6(31):31889-900. doi: 10.18632/oncotarget.5575.

16.

Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia.

Rossi D, Terzi-di-Bergamo L, De Paoli L, Cerri M, Ghilardi G, Chiarenza A, Bulian P, Visco C, Mauro FR, Morabito F, Cortelezzi A, Zaja F, Forconi F, Laurenti L, Del Giudice I, Gentile M, Vincelli I, Motta M, Coscia M, Rigolin GM, Tedeschi A, Neri A, Marasca R, Perbellini O, Moreno C, Del Poeta G, Massaia M, Zinzani PL, Montillo M, Cuneo A, Gattei V, Foà R, Gaidano G.

Blood. 2015 Oct 15;126(16):1921-4. doi: 10.1182/blood-2015-05-647925. Epub 2015 Aug 14.

17.

NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: evidence for a NOTCH1 mutation-driven epigenetic dysregulation.

Pozzo F, Bittolo T, Arruga F, Bulian P, Macor P, Tissino E, Gizdic B, Rossi FM, Bomben R, Zucchetto A, Benedetti D, Degan M, D'Arena G, Chiarenza A, Zaja F, Pozzato G, Rossi D, Gaidano G, Del Poeta G, Deaglio S, Gattei V, Dal Bo M.

Leukemia. 2016 Jan;30(1):182-9. doi: 10.1038/leu.2015.182. Epub 2015 Jul 13.

PMID:
26165233
18.

NOTCH1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatment.

Bo MD, Del Principe MI, Pozzo F, Ragusa D, Bulian P, Rossi D, Capelli G, Rossi FM, Niscola P, Buccisano F, Bomben R, Zucchetto A, Maurillo L, de Fabritiis P, Amadori S, Gaidano G, Gattei V, Del Poeta G.

Ann Hematol. 2014 Oct;93(10):1765-74. doi: 10.1007/s00277-014-2117-x. Epub 2014 Jun 13.

PMID:
24923451
19.

CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia.

Bulian P, Shanafelt TD, Fegan C, Zucchetto A, Cro L, Nückel H, Baldini L, Kurtova AV, Ferrajoli A, Burger JA, Gaidano G, Del Poeta G, Pepper C, Rossi D, Gattei V.

J Clin Oncol. 2014 Mar 20;32(9):897-904. doi: 10.1200/JCO.2013.50.8515. Epub 2014 Feb 10.

20.

Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia.

Rossi D, Spina V, Bomben R, Rasi S, Dal-Bo M, Bruscaggin A, Rossi FM, Monti S, Degan M, Ciardullo C, Serra R, Zucchetto A, Nomdedeu J, Bulian P, Grossi A, Zaja F, Pozzato G, Laurenti L, Efremov DG, Di-Raimondo F, Marasca R, Forconi F, Del Poeta G, Gaidano G, Gattei V.

Blood. 2013 Jun 13;121(24):4902-5. doi: 10.1182/blood-2013-02-486209. Epub 2013 May 1.

21.

Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia.

Rossi D, Rasi S, Spina V, Bruscaggin A, Monti S, Ciardullo C, Deambrogi C, Khiabanian H, Serra R, Bertoni F, Forconi F, Laurenti L, Marasca R, Dal-Bo M, Rossi FM, Bulian P, Nomdedeu J, Del Poeta G, Gattei V, Pasqualucci L, Rabadan R, Foà R, Dalla-Favera R, Gaidano G.

Blood. 2013 Feb 21;121(8):1403-12. doi: 10.1182/blood-2012-09-458265. Epub 2012 Dec 13.

22.

Clinical significance of c.7544-7545 delCT NOTCH1 mutation in chronic lymphocytic leukaemia.

Del Poeta G, Dal Bo M, Del Principe MI, Pozzo F, Rossi FM, Zucchetto A, Bomben R, Degan M, Rasi S, Rossi D, Bulian P, Gaidano G, Amadori S, Gattei V.

Br J Haematol. 2013 Feb;160(3):415-8. doi: 10.1111/bjh.12128. Epub 2012 Nov 20. No abstract available.

PMID:
23167503
23.

Multivalent proteoglycan modulation of FGF mitogenic responses in perivascular cells.

Cattaruzza S, Ozerdem U, Denzel M, Ranscht B, Bulian P, Cavallaro U, Zanocco D, Colombatti A, Stallcup WB, Perris R.

Angiogenesis. 2013 Apr;16(2):309-27. doi: 10.1007/s10456-012-9316-7. Epub 2012 Nov 4.

24.

Final results of a multicenter trial addressing role of CSF flow cytometric analysis in NHL patients at high risk for CNS dissemination.

Benevolo G, Stacchini A, Spina M, Ferreri AJ, Arras M, Bellio L, Botto B, Bulian P, Cantonetti M, Depaoli L, Di Renzo N, Di Rocco A, Evangelista A, Franceschetti S, Godio L, Mannelli F, Pavone V, Pioltelli P, Vitolo U, Pogliani EM; Fondazione Italiana Linfomi.

Blood. 2012 Oct 18;120(16):3222-8. doi: 10.1182/blood-2012-04-423095. Epub 2012 Aug 27.

25.

IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemia.

Bulian P, Rossi D, Forconi F, Del Poeta G, Bertoni F, Zucca E, Montillo M, Pozzato G, D'Arena G, Efremov DG, Marasca R, Lauria F, Gaidano G, Gattei V, Laurenti L.

J Transl Med. 2012 Jan 30;10:18. doi: 10.1186/1479-5876-10-18.

26.

Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia.

Rossi D, Rasi S, Fabbri G, Spina V, Fangazio M, Forconi F, Marasca R, Laurenti L, Bruscaggin A, Cerri M, Monti S, Cresta S, Famà R, De Paoli L, Bulian P, Gattei V, Guarini A, Deaglio S, Capello D, Rabadan R, Pasqualucci L, Dalla-Favera R, Foà R, Gaidano G.

Blood. 2012 Jan 12;119(2):521-9. doi: 10.1182/blood-2011-09-379966. Epub 2011 Nov 10.

27.

CD69 is independently prognostic in chronic lymphocytic leukemia: a comprehensive clinical and biological profiling study.

Del Poeta G, Del Principe MI, Zucchetto A, Luciano F, Buccisano F, Rossi FM, Bruno A, Biagi A, Bulian P, Maurillo L, Neri B, Bomben R, Simotti C, Coletta AM, Dal Bo M, de Fabritiis P, Venditti A, Gattei V, Amadori S.

Haematologica. 2012 Feb;97(2):279-87. doi: 10.3324/haematol.2011.052829. Epub 2011 Oct 11.

28.

13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia.

Dal Bo M, Rossi FM, Rossi D, Deambrogi C, Bertoni F, Del Giudice I, Palumbo G, Nanni M, Rinaldi A, Kwee I, Tissino E, Corradini G, Gozzetti A, Cencini E, Ladetto M, Coletta AM, Luciano F, Bulian P, Pozzato G, Laurenti L, Forconi F, Di Raimondo F, Marasca R, Del Poeta G, Gaidano G, Foà R, Guarini A, Gattei V.

Genes Chromosomes Cancer. 2011 Aug;50(8):633-43. doi: 10.1002/gcc.20885. Epub 2011 May 11.

PMID:
21563234
29.

Cluster analysis of immunophenotypic data: the example of chronic lymphocytic leukemia.

Zucchetto A, Cattarossi I, Nanni P, Zaina E, Prato G, Gilestro M, Marconi D, Bulian P, Rossi FM, Del Vecchio L, Omedè P, Geuna M, Del Poeta G, Gattei V.

Immunol Lett. 2011 Jan 30;134(2):137-44. doi: 10.1016/j.imlet.2010.09.017. Epub 2010 Oct 13.

PMID:
20923685
30.

Multicentre validation of a prognostic index for overall survival in chronic lymphocytic leukaemia.

Bulian P, Tarnani M, Rossi D, Forconi F, Del Poeta G, Bertoni F, Zucca E, Montillo M, Pozzato G, Deaglio S, D'Arena G, Efremov D, Marasca R, Lauria F, Gattei V, Gaidano G, Laurenti L.

Hematol Oncol. 2011 Jun;29(2):91-9. doi: 10.1002/hon.959. Epub 2010 Jul 28.

PMID:
20669154
31.

Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemia.

Buccisano F, Maurillo L, Spagnoli A, Del Principe MI, Fraboni D, Panetta P, Ottone T, Consalvo MI, Lavorgna S, Bulian P, Ammatuna E, Angelini DF, Diamantini A, Campagna S, Ottaviani L, Sarlo C, Gattei V, Del Poeta G, Arcese W, Amadori S, Lo Coco F, Venditti A.

Blood. 2010 Sep 30;116(13):2295-303. doi: 10.1182/blood-2009-12-258178. Epub 2010 Jun 14.

32.

Prognostic impact of ZAP-70 expression in chronic lymphocytic leukemia: mean fluorescence intensity T/B ratio versus percentage of positive cells.

Rossi FM, Del Principe MI, Rossi D, Irno Consalvo M, Luciano F, Zucchetto A, Bulian P, Bomben R, Dal Bo M, Fangazio M, Benedetti D, Degan M, Gaidano G, Del Poeta G, Gattei V.

J Transl Med. 2010 Mar 8;8:23. doi: 10.1186/1479-5876-8-23.

33.

Phase 2 study of intrathecal, long-acting liposomal cytarabine in the prophylaxis of lymphomatous meningitis in human immunodeficiency virus-related non-Hodgkin lymphoma.

Spina M, Chimienti E, Martellotta F, Vaccher E, Berretta M, Zanet E, Lleshi A, Canzonieri V, Bulian P, Tirelli U.

Cancer. 2010 Mar 15;116(6):1495-501. doi: 10.1002/cncr.24922.

34.

Expression of mutated IGHV3-23 genes in chronic lymphocytic leukemia identifies a disease subset with peculiar clinical and biological features.

Bomben R, Dal-Bo M, Benedetti D, Capello D, Forconi F, Marconi D, Bertoni F, Maffei R, Laurenti L, Rossi D, Del Principe MI, Luciano F, Sozzi E, Cattarossi I, Zucchetto A, Rossi FM, Bulian P, Zucca E, Nicoloso MS, Degan M, Marasca R, Efremov DG, Del Poeta G, Gaidano G, Gattei V.

Clin Cancer Res. 2010 Jan 15;16(2):620-8. doi: 10.1158/1078-0432.CCR-09-1638. Epub 2010 Jan 12.

35.

Spontaneous apoptosis and proliferation detected by BCL-2 and CD71 proteins are important progression indicators within ZAP-70 negative chronic lymphocytic leukemia.

Del Poeta G, Del Principe MI, Maurillo L, Rossi FM, Buccisano F, Ammatuna E, Simotti C, Zucchetto A, Catalano G, Bulian P, Bruno A, Venditti A, De Fabritiis P, Gattei V, Amadori S.

Leuk Lymphoma. 2010 Jan;51(1):95-106. doi: 10.3109/10428190903350421.

PMID:
20001236
36.

How would I manage a sample submitted for flow cytometry analysis for suspicious chronic lymphocytic leukaemia.

Bulian P, Del Poeta G, Gattei V.

Hematol Oncol. 2009 Dec;27(4):186-9. doi: 10.1002/hon.900. Review.

PMID:
19569256
37.

Human immunodeficiency virus-associated precursor T-lymphoblastic leukemia/lymphoblastic lymphoma: report of a case and review of the literature.

Lorenzon D, Perin T, Bulian P, De Re V, Caggiari L, Michieli M, Manuele R, Spina M, Gattei V, Fasan M, Tirelli U, Canzonieri V.

Hum Pathol. 2009 Jul;40(7):1045-9. doi: 10.1016/j.humpath.2008.12.021. Epub 2009 May 7. Review.

PMID:
19427018
38.

CD38/CD31, the CCL3 and CCL4 chemokines, and CD49d/vascular cell adhesion molecule-1 are interchained by sequential events sustaining chronic lymphocytic leukemia cell survival.

Zucchetto A, Benedetti D, Tripodo C, Bomben R, Dal Bo M, Marconi D, Bossi F, Lorenzon D, Degan M, Rossi FM, Rossi D, Bulian P, Franco V, Del Poeta G, Deaglio S, Gaidano G, Tedesco F, Malavasi F, Gattei V.

Cancer Res. 2009 May 1;69(9):4001-9. doi: 10.1158/0008-5472.CAN-08-4173. Epub 2009 Apr 21.

39.

Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study.

Bomben R, Dal Bo M, Capello D, Forconi F, Maffei R, Laurenti L, Rossi D, Del Principe MI, Zucchetto A, Bertoni F, Rossi FM, Bulian P, Cattarossi I, Ilariucci F, Sozzi E, Spina V, Zucca E, Degan M, Lauria F, Del Poeta G, Efremov DG, Marasca R, Gaidano G, Gattei V.

Br J Haematol. 2009 Feb;144(4):492-506. doi: 10.1111/j.1365-2141.2008.07469.x. Epub 2008 Nov 19.

PMID:
19036101
40.

CD49d expression is an independent risk factor of progressive disease in early stage chronic lymphocytic leukemia.

Rossi D, Zucchetto A, Rossi FM, Capello D, Cerri M, Deambrogi C, Cresta S, Rasi S, De Paoli L, Bodoni CL, Bulian P, Del Poeta G, Ladetto M, Gattei V, Gaidano G.

Haematologica. 2008 Oct;93(10):1575-9. doi: 10.3324/haematol.13103. Epub 2008 Jul 18.

41.

CD49d expression in chronic lymphocytic leukemia: a prognostic parameter and a therapeutic target.

Bulian P, Gaidano G, Del Poeta G, Gattei V.

Future Oncol. 2008 Jun;4(3):355-8. doi: 10.2217/14796694.4.3.355. No abstract available.

PMID:
18518761
42.

Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia.

Gattei V, Bulian P, Del Principe MI, Zucchetto A, Maurillo L, Buccisano F, Bomben R, Dal-Bo M, Luciano F, Rossi FM, Degan M, Amadori S, Del Poeta G.

Blood. 2008 Jan 15;111(2):865-73. Epub 2007 Oct 24.

43.

Comprehensive characterization of IGHV3-21-expressing B-cell chronic lymphocytic leukemia: an Italian multicenter study.

Bomben R, Dal Bo M, Capello D, Benedetti D, Marconi D, Zucchetto A, Forconi F, Maffei R, Ghia EM, Laurenti L, Bulian P, Del Principe MI, Palermo G, Thorsélius M, Degan M, Campanini R, Guarini A, Del Poeta G, Rosenquist R, Efremov DG, Marasca R, Foà R, Gaidano G, Gattei V.

Blood. 2007 Apr 1;109(7):2989-98.

44.

ZAP-70 expression in B-cell chronic lymphocytic leukemia: evaluation by external (isotypic) or internal (T/NK cells) controls and correlation with IgV(H) mutations.

Zucchetto A, Bomben R, Bo MD, Nanni P, Bulian P, Rossi FM, Del Principe MI, Santini S, Del Poeta G, Degan M, Gattei V.

Cytometry B Clin Cytom. 2006 Jul 15;70(4):284-92.

45.

Surface-antigen expression profiling of B cell chronic lymphocytic leukemia: from the signature of specific disease subsets to the identification of markers with prognostic relevance.

Zucchetto A, Sonego P, Degan M, Bomben R, Dal Bo M, Bulian P, Benedetti D, Rupolo M, Del Poeta G, Campanini R, Gattei V.

J Transl Med. 2006 Mar 1;4:11.

46.

CD49d in B-cell chronic lymphocytic leukemia: correlated expression with CD38 and prognostic relevance.

Zucchetto A, Bomben R, Dal Bo M, Bulian P, Benedetti D, Nanni P, Del Poeta G, Degan M, Gattei V.

Leukemia. 2006 Mar;20(3):523-5; author reply 528-9. No abstract available.

PMID:
16408095
47.

A scoring system based on the expression of six surface molecules allows the identification of three prognostic risk groups in B-cell chronic lymphocytic leukemia.

Zucchetto A, Bomben R, Dal Bo M, Sonego P, Nanni P, Rupolo M, Bulian P, Dal Maso L, Del Poeta G, Del Principe MI, Degan M, Gattei V.

J Cell Physiol. 2006 May;207(2):354-63.

PMID:
16331666
48.

The new reticulocyte parameter (RET-Y) of the Sysmex XE 2100: its use in the diagnosis and monitoring of posttreatment sideropenic anemia.

Buttarello M, Temporin V, Ceravolo R, Farina G, Bulian P.

Am J Clin Pathol. 2004 Apr;121(4):489-95.

PMID:
15080300
49.

A case of adult T cell leukemia and lymphoma in an Italian woman showing different malignant clones in tumor mass and in blood.

Menin C, Bulian P, Filippi F, Buttarello M, Casado C, Lopez-Galindez C, De Rossi A, Chieco-Bianchi L, Del Mistro A.

Haematologica. 2003 Jul;88(7):ECR23.

50.

Five fully automated methods for performing immature reticulocyte fraction: comparison in diagnosis of bone marrow aplasia.

Buttarello M, Bulian P, Farina G, Petris MG, Temporin V, Toffolo L.

Am J Clin Pathol. 2002 Jun;117(6):871-9.

PMID:
12047138

Supplemental Content

Loading ...
Support Center